Shionogi Inc. announced the FDA approval of FETROJA (cefiderocol sulfate tosylate) Intravenous injection for the treatment of certain hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This approval targets drug-resistant Gram-negative bacteria, positioning the company to address critical gaps in addressing superbug infections often immune to current therapies.